{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.5","upperLimit":"34.7","value":"23.8"},{"groupId":"OG001","lowerLimit":"9.1","upperLimit":"15.0","value":"11.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) per investigator assessment or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.\n\nBCL-2 expression was determined through central laboratory testing by immunohistochemistry (IHC) and based on a pre-specified scoring algorithm. High clinical score of 2+: ≥50% of tumor cells with moderate or higher cytoplasmic staining but \\< 50% of tumor cells with strong staining intensity; high clinical score of 3+: ≥50% of tumor cells with strong cytoplasmic staining.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23","id":"OG000","title":"Venetoclax + Bortezomib and Dexamethasone"},{"description":"Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \\& 23","id":"OG001","title":"Placebo + Bortezomib and Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization who had high BCL-2 expression","reportingStatus":"POSTED","timeFrame":"Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group","title":"Progression-Free Survival (PFS) in Participants With High B-cell Lymphoma 2 (BCL-2) Expression","type":"SECONDARY","unitOfMeasure":"months"}